Entera Bio Ltd Asset Resilience Ratio
Entera Bio Ltd asset resilience ratio. Entera Bio Ltd (ENTX) has an Asset Resilience Ratio of 0.00% as of December 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ENTX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Entera Bio Ltd (2016–2019)
Asset resilience ratio of Entera Bio Ltd from 2016 to 2019. This chart shows how Entera Bio Ltd's Asset Resilience Ratio has changed over time. Read total liabilities of Entera Bio Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Entera Bio Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ENTX total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Entera Bio Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Entera Bio Ltd Industry Peers by Asset Resilience Ratio
Compare Entera Bio Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Entera Bio Ltd Asset Resilience Ratio by Year (2016–2019)
Entera Bio Ltd asset resilience ratio by year from 2016 to 2019. The table below shows the annual Asset Resilience Ratio data for Entera Bio Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.00% | $0.00 | $16.70 Million | -- |
| 2018-12-31 | 30.10% | $4.01 Million | $13.34 Million | +29.92pp |
| 2017-12-31 | 0.17% | $23.00K | $13.28 Million | -16.93pp |
| 2016-12-31 | 17.10% | $1.07 Million | $6.29 Million | -- |
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more